The August issue of The American Journal of Gastroenterology includes clinical discussions of diet-associated NAFLD risk and increased risk of mortality from COVID-19 among PPI users. In addition, this issue features clinical research and reviews on IBS, gender barriers for CRC screening, hepatitis C, eosinophilic esophagitis, and more.
The January issue of The American Journal of Gastroenterology is now available and features new clinical research across a wide range of GI and hepatology topics, including NAFLD, colorectal cancer screening, GERD, post-COVID-19-associated functional GI disorder surges, celiac disease, and more.
Basic science research explores the effects of impaired glycine metabolism in nonalcoholic fatty liver disease – and how to potentially use glycine-based treatment to help people with NAFLD.
Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that the burden of cirrhosis in women in North America has increased substantially in recent years, a worrying trend driven by a rise in alcohol-related liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD). Projections suggest that both ALD and NAFLD rates will result in even higher cirrhosis incidence by 2040, with the most worrisome upward trends seen in young women with ALD and post-menopausal women with NAFLD.
U.S. News & World Report named University of California San Diego School of Medicine a top global university and ranked the divisions of Gastroenterology and Hepatology #1 in the world for research.
The obesity epidemic has led to an increase in the number of people who have a form of liver disease known as nonalcoholic fatty liver disease, or NAFLD. The disease can cause dangerous levels of fat to build up in…
Faculty from Wayne State University’s Eugene Applebaum College of Pharmacy and Health Sciences are leading a team of researchers to understand the causal relationships between diabetes, obesity and nonalcoholic fatty liver disease in hopes of developing a treatment.
A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.
Fatty liver disease not associated with alcohol consumption, which is called Nonalcoholic Fatty Liver Disease or NAFLD, affects more than one billion people worldwide. Even in children the numbers are overwhelming, with up to 80 percent of pediatric patients who are considered obese affected worldwide. People with NAFLD can progress to a severe form known as nonalcoholic steatohepatitis (NASH), which puts patients at higher risk for cirrhosis or liver cancer.